QT Imaging (QTI) Form 3: 325,000 Options, $1.90 Strike, Vesting Through 2028
Rhea-AI Filing Summary
Jay Walter Jennings, identified as a Director and Chief Financial Officer of QT Imaging Holdings (ticker QTI), filed an Initial Statement of Beneficial Ownership on 09/02/2025. The filing discloses a stock option covering 325,000 shares of common stock with an exercise price of $1.90 and an indicated expiration date of 09/02/2035. The option vests one-third on August 15, 2026 with the remaining two-thirds vesting in eight equal quarterly installments and fully vesting on August 15, 2028, subject to continued service.
Positive
- 325,000-share option grant disclosed, providing clear disclosure of executive equity ownership
- Exercise price of $1.90 and expiration date 09/02/2035 are explicitly stated
- Detailed vesting schedule provided: one-third on Aug 15, 2026, fully vested on Aug 15, 2028
- Reporting person identified as Director and Chief Financial Officer, fulfilling Section 16 disclosure
Negative
- None.
Insights
TL;DR: Officer/director disclosed a standard service-based option grant that ties senior management incentives to company stock.
The Form 3 confirms that Jay Walter Jennings, serving as both a director and the Chief Financial Officer, beneficially owns a stock option for 325,000 shares with a $1.90 exercise price and a 09/02/2035 expiration. The vesting schedule—one-third on August 15, 2026, then quarterly through August 15, 2028—is time-based and conditioned on continued service. This filing is routine for newly granted equity awards to named officers and satisfies Section 16 reporting obligations.
TL;DR: The disclosed equity award is sizable for an individual and follows a multi-year vesting schedule typical for retention and alignment.
The option covers 325,000 underlying shares at a $1.90 strike with a long-dated expiration (09/02/2035) and a graded vesting schedule completing on August 15, 2028. The structure suggests retention intent and aligns executive pay with future equity performance, but the filing contains no grant valuation, past holdings, or additional compensation terms to assess dilution or cost to shareholders.